A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

Phase 1Active Not RecruitingNCT07266818

Merck Sharp & Dohme LLC30 enrolled

Overview

The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

MK-1167DRUG

Oral capsule administered once daily

PlaceboDRUG

Oral capsule administered once daily

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

The key inclusion criteria but are not limited to the following: * Is in good health * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive The key inclusion criteria but are not limited to the following: * Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases * Is a smoker and/or has used nicotine or nicotine-containing products (for example, nicotine patch and electronic cigarette) within the past 3 months

Locations (1)

Hassman Research Institute Marlton Site ( Site 0001)

Marlton, New Jersey, United States

Outcomes

Primary Outcomes

Number of Participants Who Experience an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

Time frame: Up to approximately 9 weeks

Number of Participants Who Discontinue Study Treatment Due to an AE

Time frame: Up to approximately 1 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.